Engineering Versatile Bacteria‐Derived Outer Membrane Vesicles: An Adaptable Platform for Advancing Cancer Immunotherapy
Advanced Science · 2024-09 · 11 (33)
DOI: 10.1002/advs.202400049 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Science, 2024-07. Verfasst von Ziheng Luo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410013, China. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms, Bacterial Outer Membrane. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 176 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hunan Province, Scientific Research Fund of Hunan Provincial Education Department.
Abstract (Originalsprache)
In recent years, cancer immunotherapy has undergone a transformative shift toward personalized and targeted therapeutic strategies. Bacteria‐derived outer membrane vesicles (OMVs) have emerged as a promising and adaptable platform for cancer immunotherapy due to their unique properties, including natural immunogenicity and the ability to be engineered for specific therapeutic purposes. In this review, a comprehensive overview is provided of state‐of‐the‐art techniques and methodologies employed in the engineering of versatile OMVs for cancer immunotherapy. Beginning by exploring the biogenesis and composition of OMVs, unveiling their intrinsic immunogenic properties for therapeutic appeal. Subsequently, innovative approaches employed to engineer OMVs are delved into, ranging from the genetic engineering of parent bacteria to the incorporation of functional molecules. The importance of rational design strategies is highlighted to enhance the immunogenicity and specificity of OMVs, allowing tailoring for diverse cancer types. Furthermore, insights into clinical studies and potential challenges utilizing OMVs as cancer vaccines or adjuvants are also provided, offering a comprehensive assessment of the current landscape and future prospects. Overall, this review provides valuable insights for researchers involved in the rapidly evolving field of cancer immunotherapy, offering a roadmap for harnessing the full potential of OMVs as a versatile and adaptable platform for cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410013, China.
- Hunan Key Laboratory of Diagnostic and Therapeutic Drug Research for Chronic Diseases, Changsha, 410078, China.
- Institute of Physiological Chemistry and Pathobiochemistry, University of Münster, 48149, Münster, Germany.
ORCID-Profile: Fei Chen, Wenbin Zeng
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province
- Scientific Research Fund of Hunan Provincial Education Department
Zitieren
APA
Luo, Z., Cheng, X., Feng, B., Fan, D., Liu, X., Xie, R., Luo, T., Wegner, S. V., Ma, D., Chen, F., & Zeng, W. (2024). Engineering Versatile Bacteria‐Derived Outer Membrane Vesicles: An Adaptable Platform for Advancing Cancer Immunotherapy. Advanced Science, 11(33). https://doi.org/10.1002/advs.202400049
Vancouver
Luo Z, Cheng X, Feng B, Fan D, Liu X, Xie R, et al. Engineering Versatile Bacteria‐Derived Outer Membrane Vesicles: An Adaptable Platform for Advancing Cancer Immunotherapy. Advanced Science. 2024;11(33). doi:10.1002/advs.202400049
BibTeX
@article{Luo2024,
author = {Luo, Ziheng and Cheng, Xiang and Feng, Bin and Fan, Duoyang and Liu, Xiaohui and Xie, Ruyan and Luo, Ting and Wegner, Seraphine V and Ma, Dayou and Chen, Fei and Zeng, Wenbin},
title = {Engineering Versatile Bacteria‐Derived Outer Membrane Vesicles: An Adaptable Platform for Advancing Cancer Immunotherapy},
journal = {Advanced Science},
year = {2024},
volume = {11},
number = {33},
doi = {10.1002/advs.202400049}
}
EUVIMED